Serum-IgG Responses to SARS-CoV-2 After Mild and Severe COVID-19 Infection
Patients with severe symptoms and patients with mild symptoms of COVID-19 both develop SARS-CoV-2-specific IgG antibodies in serum (according to clinical trials). Patients with severe COVID-19 both seroconvert earlier and develop higher concentrations of SARS-CoV-2-specific IgG than patients with mild symptoms. Seroconverted patients with both mild and severe symptoms should still have detectable IgG levels after more than 75 days. A small percentage of patients with mild disease failed to produce detectable levels of IgG (more than 90 days PSO), but virus-neutralizing antibodies (NAbs) against SARS-CoV-2 were detected in all of these patients in the trials.
Concentrations of serum IgG over time in patients with Severe (Red) and Mild (Blue) disease (Cut-off for positive sample indicated by dotted line) in clinical trial:
PLOS ONE | https://doi.org/10.1371/journal.pone.0241104 October 21, 2020